| abstract |
The present invention relates to methods of using a G protein-coupled receptor (GPCR), for example GPR84, to identify whether a candidate compound is a modulator of atherogenesis. In certain embodiments, the GPCR couples to Gi. In certain embodiments, the GPCR is human. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of atherosclerosis and atherosclerotic disease, including coronary artery disease, myocardial infarction, peripheral arterial disease, and ischemic stroke. Agonists of the invention are additionally useful as therapeutic agents for the prevention or treatment of conditions related to MCP-I expression, including but not limited to rheumatoid arthritis, Crohn's disease, and multiple sclerosis. |